Zymeworks presented new Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing a 64.5% confirmed response rate at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The treatment demonstrated durable responses and a favorable safety profile, especially at the lower dose, with 61% progression-free survival at six months. These promising results support further clinical development of ZW191 to address limitations of current therapies and benefit a broader patient group. Zymeworks plans to continue development through partnerships or strategic collaborations.
Zymeworks' new Phase 1 data for ZW191 provides context for health sector trends. As of Oct 24, 2026 13:41 WIB, 44 of 150 US health stocks rose and 105 fell on Pluang. Notable movers include INO at USD 0.90 (+6.94%, 51% Sell / 49% Buy), HIMS at USD 27.71 (-4.87%, 74% Sell / 26% Buy), and AMLX at USD 27.20 (-4.80%).
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
Bitcoin's price fell below its 50-day moving average for the first time in 66 days, closing at $80,806, about 1.23% below the $81,807 average. This break is significant mainly for short-term trading algorithms rather than indicating a long-term trend...
